EE04453B1 - Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena - Google Patents

Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena

Info

Publication number
EE04453B1
EE04453B1 EE9700255A EE9700255A EE04453B1 EE 04453 B1 EE04453 B1 EE 04453B1 EE 9700255 A EE9700255 A EE 9700255A EE 9700255 A EE9700255 A EE 9700255A EE 04453 B1 EE04453 B1 EE 04453B1
Authority
EE
Estonia
Prior art keywords
beta
activating agent
lymphotoxin
lhc
carrier
Prior art date
Application number
EE9700255A
Other languages
English (en)
Estonian (et)
Other versions
EE9700255A (et
Inventor
L. Browning Jeffrey
Meier Werner
D. Benjamin Christopher
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE9700255A publication Critical patent/EE9700255A/xx
Publication of EE04453B1 publication Critical patent/EE04453B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EE9700255A 1995-01-26 1996-01-26 Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena EE04453B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Publications (2)

Publication Number Publication Date
EE9700255A EE9700255A (et) 1998-04-15
EE04453B1 true EE04453B1 (et) 2005-04-15

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700255A EE04453B1 (et) 1995-01-26 1996-01-26 Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena

Country Status (25)

Country Link
EP (2) EP0809510B1 (hu)
JP (2) JPH10513161A (hu)
KR (2) KR100475492B1 (hu)
CN (3) CN1589902A (hu)
AT (1) ATE268604T1 (hu)
AU (1) AU725351B2 (hu)
BG (1) BG62599B1 (hu)
BR (1) BR9606808A (hu)
CA (1) CA2211443A1 (hu)
CZ (1) CZ298711B6 (hu)
DE (1) DE69632681T2 (hu)
DK (1) DK0809510T3 (hu)
EA (1) EA000096B1 (hu)
EE (1) EE04453B1 (hu)
ES (1) ES2220972T3 (hu)
FI (1) FI119359B (hu)
HK (1) HK1006356A1 (hu)
HU (1) HUP9801746A3 (hu)
NO (1) NO322744B1 (hu)
NZ (1) NZ303405A (hu)
PL (1) PL185364B1 (hu)
PT (1) PT809510E (hu)
RO (1) RO118634B1 (hu)
SK (1) SK286497B6 (hu)
WO (1) WO1996022788A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
BR9915025A (pt) 1998-10-09 2001-08-14 Biogen Inc Reversão de choque sistêmico induzido por vìrus e insuficiência respiratória por bloqueio da via linfotoxina-beta
JP2004532608A (ja) * 2000-10-13 2004-10-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ヒト化抗ＬＴ−β−Ｒ抗体
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
JP2006515750A (ja) * 2002-12-20 2006-06-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療
KR20050094819A (ko) * 2002-12-20 2005-09-28 바이오겐 아이덱 엠에이 인코포레이티드 화학요법제와 조합된 림프독소 베타 수용체 약제
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
EP2311481A3 (en) 2006-10-20 2013-10-16 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
WO2010039714A1 (en) * 2008-09-30 2010-04-08 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists
BR112014013526A8 (pt) * 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
SG10202001779UA (en) 2015-01-20 2020-04-29 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
CA2086264C (en) * 1990-06-27 2002-12-24 Jeffrey L. Browning Surface complexed lymphotoxin
EP0672143B1 (en) * 1992-12-04 2008-06-04 Biogen Idec MA Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof

Also Published As

Publication number Publication date
HUP9801746A3 (en) 2000-11-28
MX9705629A (es) 1997-10-31
CZ236197A3 (cs) 1998-02-18
KR100475492B1 (ko) 2005-03-14
FI973118A (fi) 1997-09-25
EA000096B1 (ru) 1998-08-27
ES2220972T3 (es) 2004-12-16
SK286497B6 (sk) 2008-11-06
CZ298711B6 (cs) 2008-01-02
EP0809510B1 (en) 2004-06-09
FI973118A0 (fi) 1997-07-25
BG101855A (en) 1998-04-30
PT809510E (pt) 2004-09-30
DK0809510T3 (da) 2004-10-04
HK1006356A1 (en) 1999-02-26
BG62599B1 (bg) 2000-03-31
EP1407781A1 (en) 2004-04-14
KR100470739B1 (ko) 2005-09-02
SK98697A3 (en) 2000-02-14
EA199700144A1 (ru) 1997-12-30
ATE268604T1 (de) 2004-06-15
BR9606808A (pt) 1997-12-30
JPH10513161A (ja) 1998-12-15
WO1996022788A1 (en) 1996-08-01
EE9700255A (et) 1998-04-15
DE69632681D1 (de) 2004-07-15
CN1589902A (zh) 2005-03-09
FI119359B (fi) 2008-10-31
NO973385L (no) 1997-09-25
DE69632681T2 (de) 2005-06-09
PL185364B1 (pl) 2003-04-30
NO322744B1 (no) 2006-12-04
NO973385D0 (no) 1997-07-22
HUP9801746A2 (hu) 1998-11-30
JP2007169296A (ja) 2007-07-05
EP0809510A1 (en) 1997-12-03
KR20040102364A (ko) 2004-12-04
CA2211443A1 (en) 1996-08-01
PL321758A1 (en) 1997-12-22
CN1900116A (zh) 2007-01-24
KR19980701816A (ko) 1998-06-25
AU4970496A (en) 1996-08-14
CN1146442C (zh) 2004-04-21
AU725351B2 (en) 2000-10-12
CN1177302A (zh) 1998-03-25
NZ303405A (en) 2000-02-28
RO118634B1 (ro) 2003-08-29

Similar Documents

Publication Publication Date Title
EE04453B1 (et) Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena
AU2332188A (en) Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors
YU83600A (sh) Adenozin a3 receptorski modulatori
KIRKPATRICK et al. Stereospecific glucocorticoid binding to subcellular fractions of the sensitive and resistant lymphosarcoma P1798
EP0734264A4 (en) CONNECTIONS SPECIFICALLY BINDING TO COLORECTAL CANCER CELLS AND METHOD FOR THEIR PRODUCTION
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
IL180924A0 (en) Method for regulating cell proliferation and cell death
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
TR199701574T2 (xx) �midazol bile�imleri
EP0330201A3 (en) Method of enhancing the effect of cytotoxic agents
AU3897999A (en) Multi-analyte diagnostic system and computer implemented process for same
AU9028498A (en) System, method and cassette for mixing and delivering intravenous drugs
AU5671096A (en) Methods, nucleotide sequences and host cells for assaying ex ogenous and endogenous protease activity
DE69841164D1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
AU6152896A (en) Use of squalamine for the manufacture of a medicament
CA2298018A1 (en) Methods and compositions for inhibiting angiogenesis
AR021353A1 (es) Proceso para el procesamiento de sacarosa en glucosa.
ATE404676T1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
WO2002053195A3 (en) System for, and method of, irradiating article with x-ray beam
De Bellis et al. In vitro studies of histone glycation
Maassen et al. Comparison by photoaffinity labeling of the proteins involved in GTP hydrolysis from 70S ribosomes and a 5S RNA-protein complex from bacillus stearothermophilus
WO1996012508A3 (en) Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy
ATE267206T1 (de) 5-imino-13-deoxy-antracyclin-derivate, ihre verwendung sowie verfahren zu deren herstellung
Raleigh et al. Reductive activation of nitroaromatics and enzyme inhibition: Misonidazole and xanthine oxidase
沈锋 et al. Costimulation signals of LFA-1, LFA-2, CD44 and CD45 molecules in T cell activation

Legal Events

Date Code Title Description
HK1A Erratum in gazette
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20100126